Want to see HK:0775 full AI Analyst Report?
CK Life Sciences International (Holdings), Inc. (0775) AI Stock Analysis
CK Life Sciences International (Holdings), Inc.
(HKEX:0775)
The score is held down primarily by deteriorating financial performance—sharp margin compression, deeper losses, and a swing to negative operating and free cash flow—combined with elevated leverage. Technicals are only mildly supportive with short-term improvement but a weak longer-term trend and negative MACD. Valuation remains unattractive/unclear due to negative earnings and no dividend yield provided.
CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 4.71B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.81M
- Price to Earnings (P/E)
- -73.1
- Beta (1Y)
- 0.69
- Revenue Growth
- 0.50%
- EPS Growth
- 76.90%
- Country
- Hong Kong
- Employees
- 1,920
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model
Company Description
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceut...
How the Company Makes Money
CK Life Sciences generates revenue primarily by selling and providing life-science-based products and services across its operating segments. Key revenue streams include (1) Environmental solutions: income from pest management offerings, typically ea...
CK Life Sciences International (Holdings), Inc. Financial Statement Overview
Summary
Financial performance is weak: revenue is broadly flat, but profitability deteriorated sharply in 2025 (gross margin fell to ~14.5% and the company moved to operating losses with a wider net loss). Cash generation also worsened materially with operating cash flow slightly negative and free cash flow swinging to a large outflow (~-HK$278M). Elevated leverage (debt-to-equity rising to ~1.75) adds risk given the recent losses.
Income Statement
34NegativeBalance Sheet
43NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.52B | 5.41B | 5.52B | 5.32B | 5.28B | 5.40B |
| Gross Profit | 739.27M | 785.38M | 1.69B | 1.64B | 1.63B | 1.63B |
| EBITDA | 76.28M | -49.42M | 488.35M | 624.75M | 598.85M | 574.15M |
| Net Income | -66.34M | -188.45M | -126.55M | 17.25M | 131.96M | 162.80M |
Balance Sheet | ||||||
| Total Assets | 12.16B | 11.84B | 10.79B | 11.25B | 11.27B | 11.73B |
| Cash, Cash Equivalents and Short-Term Investments | 535.65M | 603.07M | 571.21M | 676.16M | 704.13M | 902.47M |
| Total Debt | 6.83B | 6.62B | 6.10B | 5.93B | 5.95B | 6.21B |
| Total Liabilities | 8.07B | 7.99B | 7.28B | 7.06B | 7.11B | 7.23B |
| Stockholders Equity | 3.95B | 3.78B | 3.51B | 4.19B | 4.16B | 4.50B |
Cash Flow | ||||||
| Free Cash Flow | -321.70M | -277.76M | 157.00M | 222.35M | 146.69M | 206.33M |
| Operating Cash Flow | -76.72M | -32.77M | 353.53M | 514.18M | 363.66M | 423.57M |
| Investing Cash Flow | -449.97M | -362.68M | -96.64M | -67.96M | -22.12M | -257.88M |
| Financing Cash Flow | 262.71M | 428.57M | -341.98M | -477.95M | -515.34M | -220.08M |
CK Life Sciences International (Holdings), Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Negative. The current price of 0.49 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.55, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.78 is Neutral, neither overbought nor oversold. The STOCH value of 5.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0775.
CK Life Sciences International (Holdings), Inc. Peers Comparison
Overall Rating
HK:209668Neutral
HK:269664.6Neutral
HK:117761Neutral
HK:187741.25Neutral- HK:077540Underperform
HK:167230Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2096 | 68Neutral | HKD 26.04B | 14.11 | 16.54% | 2.04% | 27.24% | 79.48% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:1177 | 61Neutral | HKD 85.83B | 30.75 | 7.56% | 2.49% | 14.57% | -31.09% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
| HK:0775 | 40Underperform | HKD 4.71B | -73.13 | -1.72% | ― | 0.50% | 76.90% |
| HK:1672 | 30Underperform | HKD 5.15B | -7.05 | -28.15% | ― | -59.39% | -130.04% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0775 | CK Life Sciences International (Holdings), Inc. | 0.49 | -0.40 | -44.94% | |
| HK:1177 | Sino Biopharmaceutical | 4.82 | -2.13 | -30.64% | |
| HK:1672 | Ascletis Pharma, Inc. | 4.90 | -4.91 | -50.05% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2096 | Simcere Pharmaceutical Group Limited | 10.14 | -2.85 | -21.96% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
CK Life Sciences International (Holdings), Inc. Corporate Events
CK Life Sciences Narrows Loss as Reorganised R&D Pipeline Advances in Oncology and Pain
CK Life Sciences reported an unaudited loss attributable to shareholders of HK$28.7 million for the first half of 2026, an 81% year-on-year reduction driven largely by a post-reorganisation change in accounting for R&D expenses. Following the sal...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026